iBET Hosts Boehringer Ingelheim’s Global Head for Biotherapeutics Discovery for Cancer Immunotherapy Seminar
iNOVA4Health Seminar: “Engaging the Immune System in the Fight Against Cancer – An Engineer’s Perspective”
On October 10th, iBET had the pleasure of welcoming Dr. Andrew E. Nixon, Head of Biotherapeutics Discovery at Boehringer Ingelheim (BI) Pharmaceuticals, Inc. (Ridgefield, CT, USA), for a seminar titled “Engaging the Immune System in the Fight Against Cancer – An Engineer’s Perspective”.
Open to the entire iNOVA4Health research unit community, the seminar offered valuable insights into BI’s approach to the discovery and engineering of T-cell engagers (TCEs), with a particular focus on the platform technologies developed by the Biotherapeutics Discovery Research group.
With over 25 years of experience in biologic drug discovery, Dr. Nixon has contributed to more than 100 antibody discovery programs, leading to numerous clinical candidates and approved biologics.
This visit highlighted the long-term ongoing collaborations with BI and allowed the discussion of future perspectives.
iBET extends its sincere thanks to Dr. Nixon for his visit and for delivering such an inspiring and informative presentation.
